Why do ms symptoms come and go

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Multiple sclerosis symptoms fluctuate due to the disease's relapsing-remitting nature, where immune attacks on myelin cause temporary neurological dysfunction. Approximately 85% of people with MS initially experience relapses lasting days to weeks, followed by partial or complete recovery periods. Specific triggers like infections (especially urinary tract infections), stress, heat exposure, and fatigue can temporarily worsen symptoms through Uhthoff's phenomenon. The underlying mechanism involves inflammatory demyelination disrupting nerve signal transmission, with symptoms improving as inflammation subsides and remyelination occurs.

Key Facts

Approximately 85% of people with MS initially present with relapsing-remitting disease
Typical MS relapses last from several days to weeks before improvement
Heat exposure can temporarily worsen symptoms in 60-80% of people with MS (Uhthoff's phenomenon)
The average annual relapse rate for untreated relapsing-remitting MS is 0.5-1.0 episodes
Approximately 50% of relapsing-remitting MS cases transition to secondary progressive MS within 15-20 years

Overview

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, first described clinically by Jean-Martin Charcot in 1868. The condition involves immune-mediated attacks on myelin, the protective sheath surrounding nerve fibers, leading to inflammation and damage that disrupts communication between the brain and body. MS affects approximately 2.8 million people worldwide, with diagnosis typically occurring between ages 20-50 and women being affected 2-3 times more frequently than men. The disease follows several patterns: relapsing-remitting MS (85% of initial cases), secondary progressive MS, primary progressive MS, and progressive-relapsing MS. Historically, MS was often misdiagnosed as hysteria or other neurological conditions until the development of MRI technology in the 1980s revolutionized diagnosis and monitoring. The first disease-modifying therapy, interferon beta-1b, was approved by the FDA in 1993, marking a significant advancement in treatment.

How It Works

The fluctuating nature of MS symptoms stems from the disease's underlying pathophysiology involving immune system dysfunction. During relapses, activated T-cells cross the blood-brain barrier and initiate inflammatory attacks on myelin, creating lesions (plaques) that disrupt nerve signal transmission. This demyelination slows or blocks electrical impulses along axons, causing temporary neurological symptoms corresponding to the affected areas. Symptoms improve during remission periods as acute inflammation subsides and partial remyelination occurs through oligodendrocyte precursor cell activation. The blood-brain barrier repairs itself, reducing further immune cell infiltration. Additionally, the nervous system can compensate through neural plasticity, where unaffected pathways take over functions of damaged areas. Temperature sensitivity (Uhthoff's phenomenon) occurs because demyelinated nerves conduct impulses less efficiently when body temperature rises, temporarily exacerbating symptoms without causing new damage.

Why It Matters

Understanding symptom fluctuation in MS is crucial for effective disease management and patient quality of life. Recognizing patterns helps distinguish true relapses requiring treatment from temporary pseudo-exacerbations triggered by factors like infection or heat. This knowledge informs treatment decisions, including the use of disease-modifying therapies that reduce relapse frequency by 30-50% and corticosteroid treatments for acute attacks. For patients, understanding symptom variability reduces anxiety about unpredictable changes and enables better lifestyle management through heat avoidance, stress reduction, and energy conservation techniques. From a research perspective, studying remission mechanisms informs development of remyelination therapies and neuroprotective strategies. The economic impact is significant, with MS costing the U.S. healthcare system approximately $28 billion annually in direct and indirect expenses.